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Background: Adults with the metabolic syndrome (MetS) are twice as likely to die from and three times as likely to
have a heart attack or stroke compared with people without the syndrome. About 70-80% of type 2 diabetes
mellitus (type 2 DM) patients are diagnosed with the MetS. Investigating the occurrence of the MetS in type 2 DM
patients is critical for cardiovascular disease prevention. We evaluated the prevalence and components of the MetS
and its associated clinical and demographic factors in a Ghanaian adult population with DM 2.
Methods: This cross-sectional study was conducted among 200 previously diagnosed type 2 DM patients receiving
care from an outpatient clinic of the Tamale Teaching Hospital, Ghana. Anthropometric measurements of waist
circumference (cm), weight (Kg) and height (m) were measured appropriately. Clinical data were obtained from the
personal health record files of the participants. MetS was defined according to the International Diabetes Federation
criteria.
Results: The prevalence of MetS was 24.0% (n=48). The prevalence was higher in women (27.3%, n= 42) compared to
men (13.0%, n=6). The commonest occurring components of the MetS included abdominal obesity (77.0%) and
elevated FPG (77.0%) denoting uncontrolled diabetes. The prevalence of elevated BP was found to be 44.0%(n=88) and
was higher in men (56.5%) than in women (40.3%). Factors that were found to be associated to the MetS were being
overweight/obese (Crude OR = 2.9, 95% CI = 1.43 – 5.90, p=0.004), ever tried to lose weight (Crude OR = 2.5, 95%
CI = 1.24 – 4.94, p=0.015) and having diabetes for over 5 years (Crude OR = 11.3, 95% CI = 5.26 – 24.08, p<0.001). Other
factors that were associated to the MetS were current smokers (Crude OR = 6.8, 95% CI = 1.21- 38.49, p=0.030) and
alcohol drinkers (Crude OR = 3.1, 95% CI = 1.23 – 7.65, p=0.018).
Conclusion: A comparatively low prevalence of the MetS was found. More females than males had the MetS.
Uncontrolled diabetes and abdominal obesity were prevalent. The factors identified by our univariate logistic
regression model were not significant predictors of the MetS in our multivariate model.
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The metabolic syndrome (MetS) as defined by the Inter-
national Diabetes Federation (IDF) is a constellation of the
most dangerous risk factors of heart attack including dia-
betes and raised fasting plasma glucose, abdominal obes-
ity, high cholesterol and high blood pressure [1-3].
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unless otherwise stated.estimated to have the MetS and are twice as likely to die
from and three times as likely to have a heart attack or
stroke compared with people without the syndrome [4].
The underlying cause of the MetS has been linked to
various forms of glucose metabolism including insulin
resistance [5], glucose intolerance [6] and abnormalities
in glucose metabolism [7]. Almost 70-80% of the popu-
lation with diabetes mellitus is diagnosed with the MetS
[8,9]. Recently a study in Nigeria reported the preva-
lence of the MetS in type 2 diabetes mellitus (type 2
DM) patients to be 86% [10]. Another study inLtd. This is an Open Access article distributed under the terms of the Creative
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IDF criteria and 60.4% on the NCEP-ATP III in persons
with type 2 DM [11]. Evidently, individuals with the
MetS have a fivefold greater risk of developing type 2
DM [4].
The co-occurrence of type 2 DM and the MetS potenti-
ates the cardiovascular risk associated with each of the
two conditions [11]. Evaluating the MetS in persons with
diabetes is thus critical for the purposes of cardiovascular
disease prevention. It is even more so in this current situ-
ation of the rising prevalence of type 2 DM in Sub-
Saharan Africa. Studies on the prevalence of the MetS
among type 2 DM patients are limited in a developing
country like Ghana and in other Sub-Saharan countries.
Accordingly, the aim of this study was to assess the
prevalence and components of the MetS among type 2
DM patients in Tamale, Ghana. Furthermore, we investi-
gated the demographic and lifestyle factors associated to
the MetS in this sample population.
Materials and methods
Participants
Two hundred previously diagnosed type 2 DM patients
receiving care from the outpatient diabetes clinic of the
Tamale Teaching Hospital, Ghana were recruited to par-
ticipate in this cross-sectional study. As described else-
where [12], all previously diagnosed diabetes patients
based on the WHO criteria [13], that sought for care
from the Hospital’s diabetes clinic, during the study
period were eligible to participate in the study. Two
hundred and fifteen participants were approached; 200
of them consented to the study, yielding a response rate
of 97.6%.The Tamale Teaching Hospital is the major re-
ferral centre for a catchment population of 4, 228,116 in-
habitants. Tamale is the capital city of the Northern
region of Ghana and located about 600km north of
Accra, the capital city of Ghana. It lies between latitude
9°22′N and longitude 0°50′W.
Informed consent was obtained from each participant.
The ethics committees of the School of Medicine and
Health Sciences of the University for Development Stud-
ies and the Tamale Teaching hospital approved the
study.
Inclusion criteria
Participants aged ≥ 30 years; clinical determined type 2
DM and duration of diabetes of at least 1 year were
qualified to participate in the study.
Exclusion criteria
Participants aged < 30 years, Pregnant and lactating
mothers were excluded from the study. Also participants
with a history of heart failure, type 1 DM, myocardial in-
farction, acromegaly, hypothyroidism, hypogonadism andany other chronic diseases; patients on prolong steroid
use, and those who were on active drug treatment for
obesity at the time of admission were excluded from the
study.
Anthropometric measurements
Anthropometric measurements of waist circumference
(cm), weight (Kg) and height (m) were measured. Waist
circumference (WC) was measured midway between the
inferior angle of the ribs and the suprailiac crest [14].
It was measured to the nearest 1 cm using a non-
stretchable fibre-glass measuring tape (Butterfly, China).
During the measurement, participants stood in an up-
right position, with arms relaxed at the side, feet evenly
spread apart and body weight evenly distributed in ac-
cordance with the WHO expert consultation report on
waist circumference and waist-hip ratio [14]. Weight
was measured to the nearest 0.1 kg using a UNICEF
electronic scale manufactured by seca. Height was mea-
sured using a wall-mounted microtoise and recorded to
the nearest 0.5 cm. BMI was calculated as weight (kg)/
height2 (m2) and used to categorize BMI-measured
weight status: underweight (BMI ≤ 18.5), normal (BMI
18.5–24.9), overweight (BMI 25.0–29.9) and obese
(BMI ≥30) [15].
Demographic and clinical parameters
Participants’ clinical parameters of systolic and diastolic
blood pressures and Fasting Plasma Glucose (FPG) were
recorded from their personal health record files. Parame-
ters such as gender, age and duration of diabetes were
also obtained from the participants by means of a pre-
designed questionnaire. Impaired Fasting Glycaemia
(IFG) was defined as FPG ≥ 6.1 mmol l-1[13]. Hypergly-
caemia was determined by a FPG ≥ 7.0 [13]. IFG and
hyperglycaemia were combined to denote uncontrolled
diabetes. Smoking habits, coffee and alcohol drinking
were also collected using the questionnaire.
Definition of the MetS
The Metabolic syndrome (MetS) was defined according to
the International Diabetes Federation (IDF) consensus
worldwide definition of the MetS [3]. According to the
new IDF definition; for a person to be defined as having
the MetS they must have: Central obesity (defined as waist
circumference (Men ≥ 94 cm and Women ≥ 80 cm) plus
any two of the following four factors: Raised triglycerides ≥
150 mg/dL (1.7 mmol/L) or specific treatment for this
lipid abnormality; Reduced HDL cholesterol < 40 mg/dL
(1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in fe-
males or specific treatment for this lipid abnormality;
Raised blood pressure (BP): systolic BP ≥ 130 or diastolic
BP ≥ 85 mm Hg or treatment of previously diagnosed
hypertension and; Raised fasting plasma glucose (FPG) ≥
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diabetes. If above 5.6 mmol/L or 100 mg/dL, OGTT is
strongly recommended but is not necessary to define pres-
ence of the syndrome. We used central obesity, raised
blood pressure and raised FPG to define the MetS in this
study.
Statistical analysis
Data were entered into Microsoft Excel 2007 and analyzed
using two statistical software packages: Graphpad Prism
version 5.00 (GraphPad software, San DiegoCalifornia
USA, www.graphpad.com) for windows and the statistical
package for the social sciences (SPSS) (version 18) for win-
dows. All continuous data were expressed as mean ± S.D
and compared using student t-test. All categorical data
were expressed as frequencies and proportions and com-
pared using Fisher’s exact test. Statistical significance was
assumed at a p-value of < 0.05. Univariate and multi-
nomial logistic regression analysis were conducted to
identify associated factors to the MetS.
Results
The background characteristics of the participants strati-
fied by gender are presented in Table 1. These 200 par-
ticipants with type 2 DM had a mean ± SD age of 56.2 ±
12.13 years in which women were significantly (p =
0.031) older than men. The mean duration of diabetes
was 5.23 ± 5.00 and significantly higher in men than in
women. The prevalence of current smokers and alcohol
drinkers were found to be 3.0% (n =6) and 11.0% (n =
22) respectively. Half (n =100) of the participants took
coffee.
The prevalence and components of the MetS stratified
by gender are presented in Table 2. The mean ± SD body
mass index (BMI) of all the participants was 23.86 ± 4.64
Kg/m2 with no significant differences between men and
women. Significantly (p < 0.001), women had largerTable 1 Background characteristics of the participants stratifi
Variable Total (n = 200)
Age (years) 56.2 ± 12.13
Duration of diabetes (years) 5.23 ± 5.00
Educational status
Low (%) 132 (66.0%)
Married
Yes (%) 48 (24.0%)
Alcohol consumption
Yes (%) 22 (11.0%)
Smoking
Yes (%) 6 (3.0%)
Coffee consumption
Yes (%) 100 (50.0%)mean WC than men with an abdominal obesity preva-
lence of 26.1% (n = 12) in men and 92.2% (n = 142) in
women. However, men had higher mean levels of sys-
tolic and diastolic blood pressures than women. Gener-
ally, the mean ± SD fasting plasma glucose (FPG) was
7.94 ± 2.81 and higher in men than in women even
though the differences were not significant. The preva-
lence of uncontrolled diabetes was 77.0% (n = 154) from
which 29.0% (n = 46) had impaired fasting glycaemia
(IFG) and the rest had hyperglycaemia (71.0%, n = 108).
The prevalence of metabolic syndrome was found to be
13.0% (n = 6) in men and 27.3% (n = 42) in women.
However, the differences were not significant (p = 0.051)
when the prevalence of metabolic syndrome was strati-
fied by gender using Fisher’s exact test.
Shown in Table 3 are the results of a univariate ana-
lysis of factors affecting the MetS. Factors that were
found to be associated to the MetS were being over-
weight/obese (Crude OR = 2.9, 95% CI = 1.43 – 5.90, p =
0.004), ever tried to lose weight (Crude OR = 2.5, 95%
CI = 1.24 – 4.94, p = 0.015) and having diabetes for over
5 years (Crude OR = 11.3, 95% CI = 5.26 – 24.08, p <
0.001). Furthermore, participants who were current
smokers had a 6.8 risk of the MetS. In addition, partici-
pants who were current drinkers (Crude OR = 3.1, 95%
CI = 1.23 – 7.65, p = 0.018) of alcohol were more likely
to develop the MetS compared to those who did not
drink alcohol.
As shown in Table 4, none of the factors identified by
our univariate logistic regression model were significant
in the MetS from our multinomial logistic regression
model.
Discussion
We report here a comparatively low prevalence of the
metabolic syndrome (MetS) in an adult Ghanaian popu-
lation with diabetes mellitus type 2 (DM).ed by gender
Men (n = 46) Women (n = 154) P value
52.83 ± 10.89 57.22 ± 12.33 0.031
6.37 ± 4.96 4.88 ± 4.98 0.023
26 (56.5%) 106 (68.8%) 0.156
12 (26.1%) 36 (23.4%) 0.698
0 (0.0%) 22 (14.3%) 0.003
0 (0.0%) 6 (3.9%) 0.340
18 (39.1%) 82 (53.2%) 0.130
Table 2 Prevalence and components of the metabolic syndrome stratified by gender
Variable Total (n = 200) Men (n = 46) Women (n = 154) P value
Metabolic Syndrome (%) 48 (24.0%) 6 (13.0%) 42 (27.3%) 0.051
WC (cm) 95.99 ± 15.63 85.17 ± 13.98 99.22 ± 14.64 < 0.001
Abdominal obesity (%) 154 (77.0%) 12 (26.1%) 142 (92.2%) < 0.001
Systolic BP (mmHg) 122.80 ± 16.17 127 ± 12.09 121.6 ± 17.04 0.014
Diastolic BP (mmHg) 84.50 ± 13.85 88.26 ± 11.80 83.38 ± 14.24 0.023
Hypertension (%) 88 (44.0%) 26 (56.5%) 62 (40.3%) 0.063
FPG (m/mol) 7.94 ± 2.81 8.07 ± 2.77 7.90 ± 2.83 0.904
Uncontrolled diabetes (%) 154 (77.0%) 34 (73.9%) 120 (77.9%) 0.556
IFG (%) 46/154 (29.9%) 12/34 (35.3%) 34/120 (28.3%) 0.525
Hypergglycaemia (%) 108/154 (70.1%) 22/34 (64.7%) 86/120 (71.7%)
BMI (Kg/m2) 23.86 ± 4.64 24.28 ± 4.56 23.74 ± 4.66 0.716
Overweight/obese (%) 64 (32.0%) 16 (34.8%) 48 (31.2%) 0.719
BMI = Body mass index, WC =Waist circumference, BP = Blood pressure, FPG = Fasting plasma glucose, IFG = Impaired Fasting Glycaemia.
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patients in Sub-Saharan Africa are limited and the few
ones that are available are variable with rates similar to
the ones reported in developed countries [16-18]. The
MetS prevalence of 24.0% reported among type 2 DM
patients in our study can be said to be among the lowest
in literature and is only comparable to the 25.2% preva-
lence of MetS among type 2 DM patients in southern
Nigeria using the WHO criteria [19]. A study among
diabetes patients in Cameroon found the prevalence of
the MetS defined by IDF to be 71.7% and 60.4% defined
by NCEP-ATP III [11]. In Nigeria, Adediran et al., [20]
reported an overall MetS prevalence of 51%, 44% in
men and 56% in women in a group of 408 type 2 DM in-
dividuals at a University Teaching Hospital in Lagos,
Nigeria based on the WHO criteria. In another Univer-
sity teaching Hospital in Northern Nigeria, Isezuo and
Ezunu reported a MetS prevalence ranging from 54–
59% among diabetic patients in 2002 [21,22]. In
Zimbabwe, Makuyana et al., [23] reported a 43% preva-
lence rate of MetS in 109 diabetic subjects in a tertiary
care diabetes clinic [24]. In some other parts of Africa,
rates of 66.8%, 85.5%, 74% among men and 87.1%,
79.7%, 93% among women, according to the NCEP-ATP
III, WHO and IDF criteria, respectively, reported in
Seychelles [25] and rates of 46% and 74% in Black and
White South Africans respectively based on the IDF cri-
teria [24]. The prevalence of the syndrome of our study
is also lower than rates reported among Caucasians
[26-28] with type-2 diabetes mellitus. From the above, it
can be said that the prevalence rates found in our study
are among the lowest so far reported in sub- Saharan
Africa. The differences could be due to the variable cri-
teria used in defining the MetS as well as ethnic differ-
ences. In addition it could be due to the fact that we didnot include HbA1c, HDL and triglycerides as criteria
for defining the MetS.
Another important finding of our study was that the
prevalence of the MetS was found to be higher in women
than in men. This is in agreement with several studies
conducted among type 2 DM patients in Sub-Saharan Af-
rica [10,11,21] and other developing countries [29-32].
However, several other studies especially in developed
countries have reported contrary findings [33-36].The
high prevalence of the MetS found among women in our
study could be due to the fact that a significant proportion
of women had abdominal obesity which is one of the com-
ponents of the MetS of the IDF criteria used in this study.
Similar reasons have also been given by several studies
that have reported higher prevalence of the MetS in
women than in men [29,37]. Women should become a
focus of high risk target screening, and attempts should
be made to normalize each component of the MetS so as
to minimize the risk of cardiovascular diseases [29].
Variable rates of the components of the MetS were
found. Similar to the findings of Ogbera [10] and Kelliny
et al [25] abdominal obesity was one of the components
of the MetS that occurred frequently. However, contrary
to their findings it was more prevalent in women than in
men. They found comparable rates between men and
women. The high prevalence of central obesity found in
our study is not surprising. Abdominal obesity is the
principal factor for defining the MetS and precedes the
other components of the MetS. Obesity is associated
with insulin resistance and contributes to hypertension,
high serum cholesterol, low HDL-c and hyperglycaemia,
and is independently associated with higher CVD risk
[38-40].
Another component of the MetS that was also found
to be prevalent in our study was hyperglycaemia and
Table 3 Univariate analysis of lifestyle demographic factors affecting the MetS
Variable n/N Rate of metabolic syndrome OR (95% CI) P value
Gender
Men 6/46 13.0% 1 1
Women 42/154 27.3% 0.4 (0.16 - 1.01) 0.051
Age (years)
≤ 40 6/20 30.0% 1 1
> 40 42/178 23.6% 1.4 (0.50 - 3.84) 0.583
Overweight/obese
Yes 20/48 41.7% 1 1
No 28/142 19.7% 2.9 (1.43 - 5.90) 0.004
Married
Yes 36/152 23.7% 1 1
No 12/48 25.0% 0.9 (0.44 - 1.98) 0.848
Educational status
Low 36/132 27.3% 1 1
High 12/68 17.6% 1.8 (0.84 - 3.64) 0.163
Ever tried to lose weight
Yes 20/54 37.0% 1 1
No 28/146 19.2% 2.5 (1.24 - 4.94) 0.015
Duration of diabetes
≤ 5 years 12/132 9.1% 11.3 (5.26 - 24.08) < 0.001
> 5 years 36/68 52.9% 1 1
Smoke
Yes 4/6 66.7% 1 1
No 44/194 22.7% 6.8 (1.21 - 38.49) 0.030
Alcohol consumption
Yes 10/22 45.5%
No 38/178 21.3% 3.1 (1.23 - 7.65) 0.018
Coffee consumption
Yes 22/100 22.0%
No 26/100 26.0% 0.8 (0.42 - 1.54) 0.620
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diabetes. Same as the prevalence rate of the abdominal
obesity, 71.0% of the participants had hyperglycaemia, a
FPG ≥ 7 mmol-1 and the rest had IFG a FPG ≥ 6.1. This
is a worrying finding in the sense that FPG values above
6.1 mmol-1 are associated with a progressively greater
risk of developing micro– and macro-vascular complica-
tions [41-43].
From our univariate analysis, participants who were
overweight/obese measured by BMI had a 2.9 risk of de-
veloping the MetS. Consistent with our findings Ogbera
[10], found that participants who had the MetS had
higher body mass indices. Also, Kip et al., [44] found
that the metabolic status was strongly related to BMI,
with 28% of women with normal BMI being dysmeta-
bolic compared with 55% among overweight women and76% among obese women in a study among women in
the US. In as much as the association between general
overweight/obese was not significant in predicting the
MetS in our multinomial logistic regression model, its
management should be considered in the treatment and
management of DM 2 patients.
Another important finding of our study was that par-
ticipants who had diabetes for over 5 years were found
to have an 11.3 risk of developing the MetS from our
univariate model. This is contrary to the findings of Shi-
majiri et al., [36] in which the prevalence of the MetS
decreased along with an increase in the duration of dia-
betes. Another study by Abdul-Ghani et al., [30] also
found an association of the MetS with less duration of
diabetes. The reasons provided by the authors of the two
studies for the decrease in the MetS with an increase in
Table 4 Multinomial logistic regression of clinical and
demographic factors affecting the MetS
Independent variables B OR (95% CI) P value
Intercept 1.47 <0.001
Overweight/obese
Yes 0.66 1.9 (0.96 – 3.94) 0.067
No 1 1 1
Ever tried to lose weight
Yes -0.80 0.4 (0.20 – 1.02) 0.055
No 1 1 1
Duration of diabetes
≤ 5 years -0.63 0.5 (0.24 – 1.21) 0.134
>5 years 1 1 1
Smoking
Yes -1.07 0.34 (0.05 – 2.55) 0.295
No 1 1 1
Alcohol consumption
Drinks alcohol -0.12 0.9 (0.26 – 3.05) 0.850
Does not drink alcohol 1 1 1
Cox and Snell = 0.070, Nagelkerke = 0.104, McFadden = 0.066.
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of medical intervention and better metabolic control in
diabetic patients due to increasing awareness with the
longer duration of diabetes. Even though, the association
of the MetS with higher duration of diabetes was found
to be non-significant in our multinomial logistic regres-
sion model, the association could be as a result of lack
of awareness as well as inadequate access to quality
medical care or lack of quality care.
Participants with the MetS were more likely to have
ever tried to lose weight, current smokers and drinkers
of alcohol. However, these factors were not significant
predictors of the MetS in our multinomial logistic re-
gression model. Further extensive studies should be con-
ducted into identifying the effects of these factors on the
MetS among DM 2 patients.
Our study is not without limitations. This was a cross-
sectional study and cannot be used to establish causality.
It however provides a basis upon which future prospect-
ive studies could be executed. FPG and blood pressure
values were obtained secondarily from the personal
health files of the diabetes patients. Although, all care
was taken to record the values to minimize errors, mis-
reporting might have occurred. The method of assess-
ment of the effect of coffee and alcohol on adiposity is
limited in the sense that we did not consider the fre-
quency and quantity of coffee/alcohol consumed. How-
ever, the findings of this study provide first-hand
information on the effect of coffee and alcohol on the
MetS and form a basis for further studies. Moreover, wedid not measure HbA1c, HDL and triglycerides in this
study due to the unavailability of funds. This may affect
the frequency of MetS. Notwithstanding these limita-
tions, this preliminary study was able to reveal important
aspects of this clinical syndrome among diabetic patients
in Ghana.
Conclusion
A comparatively low prevalence of the MetS has been
found in this study. A higher number of women than
men had the MetS. A high prevalence of abdominal
obesity was found. Majority of the participants had un-
controlled diabetes. Factors including being: generally
overweight/obese, ever tried to lose weight, having lon-
ger duration of diabetes, current smokers and alcohol
drinkers, that were found to be associated with the MetS
in our univariate analysis were not significant predictors
in our multinomial logistic regression model.
Abbreviations
ATP: National Cholesterol Education Program-Adult Treatment Panel III;
WHO: World Health Organization; IDF: International diabetes federation.
Competing interests
The right of we the authors to examine, analyze, and publish the data of the
research is not infringed upon by any contractual agreement or conflict of
interest.
Authors’ contributions
VM: Conducted analysis and Interpretation of the data, drafting of the
manuscript and critical revision of the manuscript. ZSS: Concept and Design.
RA: Data Acquisition. All authors read and approved the final manuscript.
Acknowledgements
Authors wish to thank all staff of the outpatient diabetes clinic of the Tamale
Teaching Hospital for their assistance during the data collection. We also
wish to thank the participants who voluntarily agreed to participate in the
research.
Author details
1Department of Human Biology, School of Medicine and Health Sciences,
University for Development Studies, P. O. Box TL 1883, Tamale, Ghana.
2Department of Allied Health Sciences, School of Medicine and Health
Sciences, University for Development Studies, P. O. Box TL 1883, Tamale,
Ghana.
Received: 2 January 2014 Accepted: 7 July 2014
Published: 15 July 2014
References
1. Alberti K, Zimmet P, Shaw J: Metabolic syndrome—a new world‐wide
definition: a consensus statement from the international diabetes
federation. Diabet Med 2006, 23:469–480.
2. Zimmet P, Alberti K, Serrano Ríos M: A new International Diabetes
Federation (IDF) worldwide definition of the metabolic syndrome: the
rationale and the results. Rev Esp Cardiol 2005, 58:1371–1375.
3. Alberti G, Zimmet P, Shaw J, Grundy SM: The IDF Consensus Worldwide
Definition of the Metabolic Syndrome. Brussels: International Diabetes
Federation; 2006.
4. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM: Does the
metabolic syndrome improve identification of individuals at risk of type
2 diabetes and/or cardiovascular disease? Diabetes Care 2004,
27:2676–2681.
5. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic
syndrome a comprehensive perspective based on interactions between
obesity, diabetes, and inflammation. Circulation 2005, 111:1448–1454.
Mogre et al. Journal of Diabetes & Metabolic Disorders 2014, 13:80 Page 7 of 7
http://www.jdmdonline.com/content/13/1/806. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined
metabolic syndrome, diabetes, and prevalence of coronary heart disease
among NHANES III participants age 50 years and older. Diabetes 2003,
52:1210–1214.
7. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM: The metabolic
syndrome as predictor of type 2 diabetes the San Antonio heart study.
Diabetes Care 2003, 26:3153–3159.
8. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G,
Savorani G, Zocchi D, Melchionda N: WHO and ATPIII proposals for the
definition of the metabolic syndrome in patients with type 2 diabetes.
Diabet Med 2004, 21:383–387.
9. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche
M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in
metabolic disorders: the Bruneck study. Diabetes 1998, 47:1643–1649.
10. Ogbera AO: Prevalence and gender distribution of the metabolic
syndrome. Diabetol Metab Syndr 2010, 2:4.
11. Kengne AP, Limen SN, Sobngwi E, Djouogo CF, Nouedoui C: Metabolic
syndrome in type 2 diabetes: comparative prevalence according to two
sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr
2012, 4:22–22.
12. Mogre V, Abedandi R, Salifu ZS: Distorted self-perceived weight status and
underestimation of weight status in diabetes mellitus type 2 patients.
PLoS One 2014, 9:e95165.
13. WHO: Definition, Diagnosis and Classification of Diabetes Mellitus and its
Complications, Report of a WHO Consultation. Geneva, Switzerland: WHO; 1999.
Retrieved from http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.
14. WHO: Waist Circumference and Waist–Hip Ratio, Report of a WHO Expert
Consultation. Geneva, Switzerland: WHO; 2008. Retrieved from http://
whqlibdoc.who.int/publications/2011/9789241501491_eng.pdf.
15. WHO: Obesity: Preventing and Managing the Global Epidemic, Report of a
WHO Consultation. Geneva, Switzerland: WHO; 2000. Retrieved from http://
whqlibdoc.who.int/trs/WHO_TRS_894.pdf?ua=1.
16. Okafor CI: Metabolic syndrome in Africa: current trends. Indian J
Endocrinol Metab 2012, 16:56–66.
17. Faergeman O: The atherosclerosis epidemic: methodology, nosology, and
clinical practice. Am J Cardiol 2001, 88:4–7.
18. Fezeu L, Balkau B, Kengne A-P, Sobngwi E, Mbanya J-C: Metabolic
syndrome in a sub-Saharan African setting: central obesity may be the
key determinant. Atherosclerosis 2007, 193:70–76.
19. Alebiosu CO, Odusan BO: Metabolic syndrome in subjects with type-2
diabetes mellitus. J Natl Med Assoc 2004, 96:817.
20. Adediran O, Edo A, Jimoh A, Ohwovoriole A: Prevalence of the metabolic
syndrome among Nigerians with type 2 diabetes. Diabetes Int 2007,
15:13–14.
21. Isezuo S, Ezunu E: Demographic and clinical correlates of metabolic
syndrome in Native African type-2 diabetic patients. J Natl Med Assoc
2005, 97:557.
22. Isezuo S: Is high density lipoprotein cholesterol useful in diagnosis of
metabolic syndrome in native Africans with type 2 diabetes? Ethn Dis
2005, 15:6.
23. Makuyana D, Gomo Z, Munyombwe T, Matenga J, Hakim J: Metabolic
syndrome disorders in urban black Zimbabweans with type 2 diabetes
mellitus. Cent Afr J Med 2004, 50:24.
24. Kalk W, Joffe B: The metabolic syndrome, insulin resistance, and its
surrogates in African and white subjects with type 2 diabetes in South
Africa. Metab Syndr Relat Disord 2008, 6:247–255.
25. Kelliny C, William J, Riesen W, Paccaud F, Bovet P: Metabolic syndrome
according to different definitions in a rapidly developing country of the
African region. Cardiovasc Diabetol 2008, 7:27.
26. Abdul-Rahim HF, Husseini A, Bjertness E, Giacaman R, Gordon NH, Jervell J:
The metabolic syndrome in the West Bank population an urban-rural
comparison. Diabetes Care 2001, 24:275–279.
27. Balkau B, Charles M-A, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin
JS, Morris R, Zavaroni I, van Dam R, Feskins E: Frequency of the WHO
metabolic syndrome in European cohorts, and an alternative definition
of an insulin resistance syndrome. Diabetes Metabol 2002, 28:364–376.
28. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Cerai SP,
Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause
and cardiovascular mortality in type 2 diabetes the Casale Monferrato
study. Diabetes Care 2004, 27:2689–2694.29. Raman R, Gupta A, Pal SS, Ganesan S, Venkatesh K, Kulothungan V, Sharma
T: Prevalence of metabolic syndrome and its influence on microvascular
complications in the Indian population with type 2 diabetes mellitus:
Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular
Genetic Study (SN-DREAMS, report 14). Diabetol Metab Syndr 2010, 2:67.
30. Abdul-Ghani M, Nawaf G, Fawaz G, Itzhak B, Minuchin O, Vardi P: Increased
prevalence of microvascular complications in type 2 diabetes patients
with the metabolic syndrome. IMAJ-RAMAT GAN- 2006, 8:378.
31. Nahar S, Rahman M, Ullah M, Debnath B, Sultana N, Farhad C: Prevalence
of metabolic syndrome in newly diagnosed type 2 diabetes mellitus.
Cardiovasc J 2011, 4:17–25.
32. Dhanaraj E, Bhansali A, Jaggi S, Dutra P, Jain S, Tiwari P, Ramarao P:
Prevalence and predictors of metabolic syndrome in non-obese Asian
Indians with newly detected type 2 diabetes mellitus. J Indian Med Assoc
2008, 106:366–368. 370-362.
33. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome
among US adults: findings from the third national health and nutrition
examination survey. JAMA 2002, 287:356–359.
34. Kumar SV, Nagesh A, Leena M, Shravani G, Chandrasekar V: Incidence of
metabolic syndrome and its characteristics of patients attending a
diabetic outpatient clinic in a tertiary care hospital. J Nat Sci Biol Med
2013, 4:57.
35. Puepet FH, Ohwovoriole AE: Prevalence of risk factors for diabetes
mellitus in a non-diabetic population in Jos, Nigeria. Niger J Med 2008,
17:71–74.
36. Shimajiri Y, Tsunoda K, Furuta M, Kadoya Y, Yamada S, Nanjo K, Sanke T:
Prevalence of metabolic syndrome in Japanese type 2 diabetic patients
and its significance for chronic vascular complications. Diabetes Res Clin
Pract 2008, 79:310–317.
37. Surana S, Shah D, Gala K, Susheja S, Hoskote S, Gill N, Joshi S, Panikar V:
Prevalence of metabolic syndrome in an urban Indian diabetic
population using the NCEP ATP III guidelines. JAPI 2008, 56:865–868.
38. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens E, Pyörälä K: Plasma insulin
and cardiovascular mortality in non-diabetic European men and women:
a meta-analysis of data from eleven prospective studies.
Diabetologia 2004, 47:1245–1256.
39. Zimmet P, Alberti K, Shaw J: Global and societal implications of the
diabetes epidemic. Nature 2001, 414:782–787.
40. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willet WC, Rosner BA, Speizer
FE, Manson JE: Body fat distribution and risk of non-insulin-dependent
diabetes mellitus in women the nurses’ health study. Am J Epidemiol
1997, 145:614–619.
41. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ,
Badran A, Sous ES, Ali MA: Comparison of fasting and 2-hour glucose and
HbA1c levels for diagnosing diabetes: diagnostic criteria and
performance revisited. Diabetes Care 1997, 20:785–791.
42. Alberti K: The clinical implications of impaired glucose tolerance. Diabet
Med 1996, 13:927–937.
43. McCance D, Hanson R, Pettitt D, Bennett P, Hadden D, Knowler W:
Diagnosing diabetes mellitus–do we need new criteria?
Diabetologia 1997, 40:247–255.
44. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, Rogers WJ,
Reis SE: Clinical importance of obesity versus the metabolic syndrome in
cardiovascular risk in women a report from the Women’s Ischemia
Syndrome Evaluation (WISE) study. Circulation 2004, 109:706–713.
doi:10.1186/2251-6581-13-80
Cite this article as: Mogre et al.: Prevalence, components and associated
demographic and lifestyle factors of the metabolic syndrome in type 2
diabetes mellitus. Journal of Diabetes & Metabolic Disorders 2014 13:80.
